Search

Your search keyword '"Ciara Freeman"' showing total 23 results
Start Over Author "Ciara Freeman" Publication Year Range Last 10 years
23 results on '"Ciara Freeman"'

1. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience

Author

Hamza Hashmi, Doris K. Hansen, Lauren C. Peres, Omar Castaneda Puglianini, Ciara Freeman, Gabriel De Avila, Surbhi Sidana, Leyla Shune, Douglas W. Sborov, James Davis, Charlotte Wagner, Mehmet H. Kocoglu, Shebli Atrash, Peter Voorhees, Gary Simmons, Christopher Ferreri, Nilesh Kalariya, Larry D. Anderson Jr., Aimaz Afrough, Danai Dima, Jack Khouri, Joseph McGuirk, Fred Locke, Rachid Baz, Krina K. Patel, and Melissa Alsina

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

While response rates and survival outcomes have been very promising for idecabtagene vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell maturation antigen (BCMA) targeted chimeric antigen receptor (CAR) T-cell therapy. Understanding the characteristics of these patients is important for patient selection and development of novel strategies to improve outcomes. We evaluated factors associated with early progression (progression or death due to myeloma ≤3 months after CAR T-cell infusion) in patients treated with standard of care ide-cel at 11 US academic centers. Among 211 patients that received ide-cel, 43 patients had a progressive event ≤3 months of infusion. Patients with a history of extramedullary disease, prior BCMA targeted therapy, elevated ferritin at lymphodepletion, use of bridging therapy, Hispanic ethnicity, plasma cell leukemia and t(4;14) were more likely to progress ≤3 months of infusion (P

Published
2023
Full Text
View/download PDF

2. Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment

Author

Surbhi Sidana, Lauren C. Peres, Hamza Hashmi, Hitomi Hosoya, Christopher Ferreri, Jack Khouri, Danai Dima, Shebli Atrash, Peter Voorhees, Gary Simmons, Douglas W. Sborov, Nilesh Kalariya, Vanna Hovanky, Sushma Bharadwaj, David Miklos, Charlotte Wagner, Mehmet H. Kocoglu, Gurbakhash Kaur, James A. Davis, Shonali Midha, Murali Janakiram, Ciara Freeman, Melissa Alsina, Frederick Locke, Rebecca Gonzalez, Yi Lin, Joseph McGuirk, Aimaz Afrough, Leyla Shune, Krina K. Patel, and Doris K. Hansen

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

We evaluated patients with relapsed multiple myeloma with renal impairment (RI) treated with standard of care idecabtagene vicleucel (ide-cel), as outcomes with chimeric antigen receptor (CAR) T-cell therapy are unknown in this population. RI was defined as creatinine clearance (CrCl)

Published
2023
Full Text
View/download PDF

3. Single-cell profiling reveals a memory B cell-like subtype of follicular lymphoma with increased transformation risk

Author

Xuehai Wang, Michael Nissen, Deanne Gracias, Manabu Kusakabe, Guillermo Simkin, Aixiang Jiang, Gerben Duns, Clementine Sarkozy, Laura Hilton, Elizabeth A. Chavez, Gabriela C. Segat, Rachel Wong, Jubin Kim, Tomohiro Aoki, Rashedul Islam, Christina May, Stacy Hung, Kate Tyshchenko, Ryan R. Brinkman, Martin Hirst, Aly Karsan, Ciara Freeman, Laurie H. Sehn, Ryan D. Morin, Andrew J. Roth, Kerry J. Savage, Jeffrey W. Craig, Sohrab P. Shah, Christian Steidl, David W. Scott, and Andrew P. Weng

Subjects
Science
Abstract

Follicular lymphoma can transform to a more aggressive histology. Here, the authors use bulk and single cell analysis to create a 26 marker panel which could be used to profile FL samples and predict the risk of transformation using flow cytometry.

Published
2022
Full Text
View/download PDF

4. P1540: COVID-19 INFECTION AMONG CAR-T CELL THERAPY RECIPIENTS: A SINGLE CENTER EXPERIENCE

Author

Mohammad Ammad Ud Din, Nayeon Oh, Aliyah Baluch, Olga Klinkova, Rod Quilitz, Melissa Alsina, Nelli Bejanyan, Omar Castaneda, Julio Chavez, Hany Elmariah, Ciara Freeman, Doris Hansen, Michael Jain, Farhad Khimani, Aleksandr Lazaryan, Hien Liu, Asmita Mishra, Leonel Ochoa, Lia Perez, Joseph Pidala, Bijal Shah, Taiga Nishihori, Frederick Locke, and Rawan Faramand

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

5. PB2092: INCIDENCE AND RISK FACTORS ASSOCIATED WITH BLEEDING FOLLOWING ANTI-B CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Author

Turab Mohammed, Moazzam Shahzad, Lauren Peres, Sushmita Khadka, Christelle Colinleitzinger, Abida Babu, William Doyle, Omar Castaneda Puglianini, Laura Oswald, Gabe De Avila, Ariel Grajales-Cruz, Brandon Blue, Jose Ochoa-Bayona, Eric Smith, Salvatore Corallo, Farhad Khimani, Rawan Faramand, Hany Elmariah, Aleksandr Lazaryan, Michael Jain, Hien Liu, Taiga Nishihori, Ken Shain, Rachid Baz, Melissa Alsina, Frederick Locke, Ciara Freeman, and Doris Hansen

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

6. Hematopoietic Recovery after Anti-B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T Cell Therapy (CAR T), Idecabtagene Vicleucel (Ide-cel), for Relapsed/ Refractory Multiple Myeloma (RRMM)

Author

Razan Mohty, Dimitrios Drekolias, Lauren Peres, Ciara Freeman, Omar Castaneda, Rawan G Faramand, Laura Oswald, Kayla Reid, Gabe De Avila, Brandon Jamaal Blue, Ariel Grajales, Turab Mohammed, Jose Ochoa-Bayona, Alexandria M Shrewsbury, William Doyle, Rebecca Gonzalez, Jennifer Logue, Hany Elmariah, Michael D Jain, Hien Liu, Jason Brayer, Kenneth Shain, Rachid Baz, Melissa Alsina, Taiga Nishihori, Marco L. Davila, Frederick L. Locke, and Doris K Hansen

Subjects
Transplantation, Molecular Medicine, Immunology and Allergy, Cell Biology, Hematology
Published
2023
Full Text
View/download PDF

7. Fludarabine Exposure Impact on Safety and Efficacy of Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Filip Ionescu, Ciara Freeman, Omar Castaneda, Brandon Jamaal Blue, Ariel Grajales, Cole T. Powell, Gabe De Avila, Lauren Peres, Laura Oswald, Leonel Ochoa, Alexandria M Shrewsbury, Kristy Harvey, Catherine Quealy, Christina A Bachmeier, Rebecca Gonzalez, Jennifer Logue, Rawan G Faramand, Hany Elmariah, Michael D Jain, Hien Liu, Jason Brayer, Taiga Nishihori, Kenneth Shain, Rachid Baz, Melissa Alsina, Frederick L. Locke, Philipp M Altrock, and Doris K Hansen

Subjects
Transplantation, Molecular Medicine, Immunology and Allergy, Cell Biology, Hematology
Published
2023
Full Text
View/download PDF

8. Baseline Levels of Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Author

Doris K Hansen, Lauren Peres, Ciara Freeman, Omar Castaneda, Rawan G Faramand, Laura Oswald, Kayla Reid, Gabe De Avila, Brandon Jamaal Blue, Ariel Grajales, Leonel Ochoa, Alexandria M Shrewsbury, William Doyle, Cole T. Powell, Turab Mohammed, Rebecca Gonzalez, Jennifer Logue, Farhad Khimani, Hany Elmariah, Michael D Jain, Hien Liu, Jason Brayer, Taiga Nishihori, Kenneth Shain, Rachid Baz, Melissa Alsina, Marco L. Davila, and Frederick L. Locke

Subjects
Transplantation, Molecular Medicine, Immunology and Allergy, Cell Biology, Hematology
Published
2023
Full Text
View/download PDF

9. Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience

Author

Filip Ionescu, Eloho Ajayi, Aamia Leach, Melissa Alsina, Nelli Bejanyan, Omar Castaneda, Hany Elmariah, Ciara Freeman, Doris K Hansen, Michael D Jain, Farhad Khimani, Aleksandr Lazaryan, Hien Liu, Frederick L. Locke, Asmita Mishra, Dr. Michael L. Nieder, Leonel Ochoa, Lia Elena Perez, Joseph A. Pidala, Rod Quilitz, Olga V Klinkova, Aliyah Baluch, Taiga Nishihori, and Rawan G Faramand

Subjects
Transplantation, Molecular Medicine, Immunology and Allergy, Cell Biology, Hematology
Published
2023
Full Text
View/download PDF

10. Anti-BCMA CAR T-Cell Commercial Slot Allocation in Patients with Relapsed/Refractory Multiple Myeloma: Insights from a Single Center Experience

Author

Omar Castaneda Puglianini, Doris K Hansen, Ariel Grajales-Cruz, Brandon Jamaal Blue, Jason Brayer, Ciara Freeman, Kenneth Shain, Hien Liu, Leonel Ochoa, Frederick L. Locke, Rachid Baz, Melissa Alsina, and Taiga Nishihori

Subjects
Transplantation, Molecular Medicine, Immunology and Allergy, Cell Biology, Hematology
Published
2023
Full Text
View/download PDF

11. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis

Author

Anthony C. Wood, Ariel Perez Perez, Brian Arciola, Kedar Patel, Grace Johnson, Elizabeth DiMaggio, Christina A. Bachmeier, Kayla Reid, Salvatore Carallo, Melanie H. Vargas, Rawan Faramand, Julio C. Chavez, Bijal Shah, Sameh Gaballa, Farhad Khimani, Hany Elmariah, Taiga Nishihori, Aleksandr Lazaryan, Ciara Freeman, Marco L. Davila, Frederick L. Locke, Rahul Mhaskar, Claude Bassil, and Michael D. Jain

Subjects
Transplantation, Receptors, Chimeric Antigen, Antigens, CD19, Cell- and Tissue-Based Therapy, Cell Biology, Hematology, Acute Kidney Injury, Kidney, Immunotherapy, Adoptive, United States, Cohort Studies, Renal Dialysis, Humans, Kidney Failure, Chronic, Cytokines, Molecular Medicine, Immunology and Allergy, Lymphoma, Large B-Cell, Diffuse, Cytokine Release Syndrome, Retrospective Studies
Abstract

Patients with renal impairment (RI) are typically excluded from trials evaluating chimeric antigen receptor (CAR) T cell therapies. We evaluated the outcomes of patients with RI receiving standard of care (SOC) CAR T cell therapy for relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). In this retrospective, single-center cohort study of patients with R/R DLBCL treated with SOC axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) after 2 or more prior lines of therapy, renal and survival outcomes were compared based on RI and fludarabine dose reduction (DR) status. RI was defined by an estimated glomerular filtration rate60 mL/min/1.73 m

Published
2022
Full Text
View/download PDF

12. Measurable Residual Disease Outcompetes Cytogenetics in Predicting Leukemia Free Survival Following Allogeneic Stem Cell Transplantation Outcomes in Adults with Acute Lymphoblastic Leukemia

Author

Rawan G Faramand, Biwei Cao, Abu-Sayeef Mirza, Jongphil Kim, Silvia Tse Bunting, Omar Castaneda, Marco L. Davila, Hany Elmariah, Ciara Freeman, Doris K Hansen, Michael D Jain, Farhad Khimani, Frederick L. Locke, Hien Liu, Joseph A. Pidala, Leonel Ochoa, Asmita Mishra, Michael L. Nieder, Taiga Nishihori, Melissa Alsina, Lia Elena Perez, Bijal Shah, Claudio Anasetti, Nelli Bejanyan, and Aleksandr Lazaryan

Subjects
Transplantation, Molecular Medicine, Immunology and Allergy, Cell Biology, Hematology
Published
2022
Full Text
View/download PDF

13. CD40 Ligand Blockade Prevents Acute Gvhd: Results from a Multicenter Phase I-Ib Trial

Author

Farhad Khimani, Haris Ali, Brian C. Betts, Jongphil Kim, Hany Elmariah, Lia Elena Perez, Taiga Nishihori, Christopher Cubitt, Michael L. Nieder, Nelli Bejanyan, Frederick L. Locke, Melissa Alsina, Rawan G Faramand, Asmita Mishra, Michael D Jain, Aleksandr Lazaryan, Leonel Ochoa, Doris K Hansen, Omar Castaneda, Ciara Freeman, Marco L. Davila, Hien Liu, Ram Thapa, Claudio Anasetti, Hannah Choe, and Joseph A. Pidala

Subjects
Transplantation, Molecular Medicine, Immunology and Allergy, Cell Biology, Hematology
Published
2022
Full Text
View/download PDF

14. Impact of Obesity on Lymphodepletion and Outcomes Following Idecabtagene Vicleucel in Multiple Myeloma

Author

Doris K Hansen, Alexandria M Shrewsbury, Lauren Peres, Jessica Provencher, Taiga Nishihori, Hien Liu, Jason Brayer, Omar Castaneda, Brandon Jamaal Blue, Leonel Ochoa, Ciara Freeman, Jennifer Logue, Hany Elmariah, Rawan G Faramand, Michael D Jain, Aleksandr Lazaryan, Nelli Bejanyan, Lia Elena Perez, Michael L. Nieder, Asmita Mishra, Joseph A. Pidala, Marco L. Davila, Kenneth Shain, Rachid Baz, Frederick L. Locke, and Melissa Alsina

Subjects
Transplantation, Molecular Medicine, Immunology and Allergy, Cell Biology, Hematology
Published
2022
Full Text
View/download PDF

15. Cytopenia and Infection Early after Standard of Care Idecabtagene Vicleucel in Multiple Myeloma

Author

Jennifer Logue, Lauren Peres, Alexandria M Shrewsbury, Jessica Provencher, Taiga Nishihori, Hien Liu, Jason Brayer, Omar Castaneda, Brandon Jamaal Blue, J. Leonel Ochoa-Bayona, Ciara Freeman, Hany Elmariah, Rawan G Faramand, Michael D Jain, Aleksandr Lazaryan, Nelli Bejanyan, Lia Elena Perez, Michael L. Nieder, Asmita Mishra, Joseph A. Pidala, Marco L. Davila, Kenneth Shain, Rachid Baz, Melissa Alsina, Frederick L. Locke, and Doris K Hansen

Subjects
Transplantation, Molecular Medicine, Immunology and Allergy, Cell Biology, Hematology
Published
2022
Full Text
View/download PDF

16. Outcomes of CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma in Patients with Reduced Renal Function Including Dialysis

Author

Anthony C Wood, Brian Arciola, Kedar Patel, Grace Johnson, Ariel Perez Perez, Christina A Bachmeier, Elizabeth DiMaggio, Julio C. Chavez, Bijal Shah, Sameh Gaballa, Farhad Khimani, Taiga Nishihori, Aleksandr Lazaryan, Ciara Freeman, Marco L. Davila, Frederick L. Locke, Rahul Mhaskar, Claude Bassil, and Michael D Jain

Subjects
Transplantation, Molecular Medicine, Immunology and Allergy, Cell Biology, Hematology
Published
2022
Full Text
View/download PDF

18. Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed/refractory multiple myeloma (RRMM) patients treated with idecabtagene vicleucel (ide-cel; bb2121), an anti-BCMA CAR T cell therapy

Author

Julie Rytlewski, Jaymes Fuller, David R. Mertz, Ciara Freeman, Salomon Manier, Nina Shah, and Timothy Brandon Campbell

Subjects
Cancer Research, Oncology
Abstract

8021 Background: The anti-BCMA autologous CAR T cell therapy ide-cel has achieved deep and durable responses in RRMM patients (Munshi, N Engl J Med 2021). Prior studies have described the correlation between patient characteristics and clinical outcomes from CD19 CAR T cell therapy (Finney, J Clin Invest 2019; Fraietta, Nat Med 2018). We sought to define patient profiles correlated with manufacturing and clinical endpoints in RRMM patients treated with ide-cel in clinical trials using unsupervised clustering and multivariate machine learning across multiple key variable domains. Methods: Clinical and manufacturing data were harmonized across 164 RRMM patients treated with ide-cel in KarMMa (NCT03361748) and KarMMa-2 cohort 1 (NCT03601078). Based on individual multivariate importance, 10 selected peripheral blood mononuclear cell (PBMC), drug product (DP), and in-process cell growth variables were used to define patient clusters. Random forest classifiers were generated to identify patient characteristics associated with manufacturing and clinical endpoints. Wilcoxon rank sum and Kruskal-Wallis tests were used to compare 2 and 3+ categorical groups; Cox proportional hazards were used to compare groups with time-to-event data. Results: Using an unsupervised method, 4 patient clusters were identified that represented 10%, 57%, 15%, and 18%, respectively, of the total 164 patients. Cluster 4 was the most favorable and was characterized by a higher frequency of T cells in PBMCs; increased T-cell size during manufacturing; higher DP T-cell transduction, potency, and vector copy number; and ultimately a > 3-fold higher CAR T cell yield compared with the least favorable cluster 1. Cluster 2 contained most patients and was associated with intermediate manufacturing endpoints. Patients in cluster 4 had a higher complete response rate, longer progression-free survival, and were defined by lower tumor burden, higher absolute lymphocyte count (ALC), and longer washout period after alkylator treatment, among others (Table). Conclusions: The current study identified patient profiles in RRMM using accessible laboratory or medical history data that correlated with longitudinal outcomes. These findings may inform patients likely to achieve improved outcomes with CAR T cell therapy. Clinical trial information: NCT03361748. [Table: see text]

Published
2022
Full Text
View/download PDF

19. Late effects in survivors treated for lymphoma as adolescents and young adults: a population-based analysis

Author

Andrea C, Lo, Ben, Chen, Vanessa, Samuel, Kerry J, Savage, Ciara, Freeman, and Karen, Goddard

Subjects
Adult, Young Adult, Adolescent, Lymphoma, Lymphoma, Non-Hodgkin, Humans, Neoplasms, Second Primary, Survivors, Hodgkin Disease
Abstract

The study objective is to describe and quantify the incidence of treatment-induced late effects in AYA lymphoma patients.Consecutive patients diagnosed with Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL) at 15-24 years of age were identified. All patients in British Columbia who received radiation therapy (RT) from 1974 to 2014 with ≥ 5-year survival post-RT were included. Late effects' analyses included only survivors who received RT to the relevant anatomical site(s) and/or relevant chemotherapy, and were reported as cumulative incidence (CI) ± standard error.Three hundred and five patients were identified (74% HL). Median age of diagnosis was 21 years. Median follow-up was 19.1 years for secondary malignancy and 7.2 years for other endpoints. Hypothyroidism was the most prevalent late effect, with a CI of 22.4 ± 2.8% and 35.1 ± 4% at 5 and 10 years, respectively. CI of in-field secondary malignancy was 0.4 ± 0.4% at 10 years and 2.8 ± 1.2% at 20 years. CI of symptomatic pulmonary toxicity was 4.6 ± 1.5% and 6.8 ± 2.0% at 5 and 10 years, respectively, and was higher in patients receiving multiple RT courses (p = 0.009). Esophageal complications occurred at a CI of 1.4 ± 0.8% at 5 years and 2.2 ± 1.1% at 10 years. CI of xerostomia/dental decay was 2.6 ± 1.3% at 5 years and 4.9 ± 2.1% at 10 years. CI of cardiac disease was at 2.3 ± 0.9% at 5 years and 4.4 ± 1.5% at 10 years. CI of infertility was 6.5 ± 1.6% at 5 years and 9.4 ± 2.1% at 10 years.Survivors of AYA lymphoma have a high incidence and diverse presentation of late effects.AYA lymphoma survivors should be educated about their risks of late effects and offered screening and follow-up when appropriate.

Published
2020

20. Marrow Myeloma Burden and Idecabtagene Vicleucel Outcomes in the Standard of Care Setting

Author

Doris K Hansen, Alexandria M Shrewsbury, Lauren Peres, Jessica Provencher, Taiga Nishihori, Hien Liu, Jason Brayer, Omar Castaneda, Brandon Jamaal Blue, Leonel Ochoa, Ciara Freeman, Jennifer Logue, Hany Elmariah, Rawan G Faramand, Michael D Jain, Aleksandr Lazaryan, Nelli Bejanyan, Lia Elena Perez, Michael L. Nieder, Asmita Mishra, Joseph A. Pidala, Marco L. Davila, Kenneth Shain, Rachid Baz, Melissa Alsina, and Frederick L. Locke

Subjects
Transplantation, Molecular Medicine, Immunology and Allergy, Cell Biology, Hematology
Published
2022
Full Text
View/download PDF

21. Prospective Cohort Study of Immune Suppression Taper and Discontinuation

Author

Joseph A. Pidala, Ram Thapa, Jongphil Kim, Asmita Mishra, Doris K Hansen, Rawan G Faramand, Mohamed A. Kharfan-Dabaja, Aleksandr Lazaryan, Farhad Khimani, Nelli Bejanyan, Michael L. Nieder, Taiga Nishihori, Hien Liu, Melissa Alsina, Omar Castaneda, Marco L. Davila, Hany Elmariah, Ciara Freeman, Michael D Jain, Frederick L. Locke, Leonel Ochoa, Brian C. Betts, Lia Elena Perez, Ernesto Ayala, Paula Keskula, Alexandre Albanese, Claudio Anasetti, and Leslie S. Kean

Subjects
Transplantation, Molecular Medicine, Immunology and Allergy, Cell Biology, Hematology
Published
2022
Full Text
View/download PDF

22. CARDIAC EVENTS AFTER ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR T-CELL (IDECABTAGENE VICLEUCEL) FOR MULTIPLE MYELOMA

Author

Dae Hyun Lee, Sanjay Amrith Chandrasekhar, Michael Jain, Doris Hansen, Ciara Freeman, Melissa Alsina, Rachid Baz, Omar Castaneda Puglianini, Hien Liu, Brandon Blue, Marco L. Davila, Rawan Faramand, Abhishek Kumar, Bijal Shah, Aleksandr Lazaryan, Farhad Khimani, Taiga Nishihori, Christina Bachmeier, Frederick Locke, Guilherme Henrique Oliveira, and Mohammed Alomar

Subjects
Cardiology and Cardiovascular Medicine
Published
2022
Full Text
View/download PDF

23. High-resolution architecture and partner genes of

Author

Lauren C, Chong, Susana, Ben-Neriah, Graham W, Slack, Ciara, Freeman, Daisuke, Ennishi, Anja, Mottok, Brett, Collinge, Pau, Abrisqueta, Pedro, Farinha, Merrill, Boyle, Barbara, Meissner, Robert, Kridel, Alina S, Gerrie, Diego, Villa, Kerry J, Savage, Laurie H, Sehn, Reiner, Siebert, Ryan D, Morin, Randy D, Gascoyne, Marco A, Marra, Joseph M, Connors, Andrew J, Mungall, Christian, Steidl, and David W, Scott

Subjects
Gene Rearrangement, Male, Proto-Oncogene Proteins c-myc, Lymphoid Neoplasia, immune system diseases, hemic and lymphatic diseases, Humans, Female, Lymphoma, Large B-Cell, Diffuse, Middle Aged, Aged
Abstract

One third of MYC rearrangements in DLBCL occur in a cluster upstream of the MYC coding sequence and are enriched for IGH partners.Most MYC rearrangements in HGBL-DH patients have non-IG partners.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results